Table 1.
Patients with detectable lymphoma at time of T-cell infusion
| Patient ID | Age, y/sex | Disease, stage at diagnosis | No. of relapses | Most recent treatment (time before CTL infusion) | Total CTL dose, m−2 | Response to CTL infusion (survival mo) |
|---|---|---|---|---|---|---|
| 1 | 8/M | T-cell SCAEBV | 2 | Syngeneic SCT: BU/CY/ alemtuzumab (5 mo) | 4 × 107 | PR (> 36 mo) |
| 2* | 39/M | CD30+ B-cell NHL stage IVb | 5 (refractory disease for 2 y) | Anti-CD30 (11 mo) | 8 × 107 | CR (relapsed 10 mo, died 33 mo) |
| 3* | 30/F | Mixed cellularity HD stage IVb | 2 | ABVD (12 mo) rituximab (1 mo) | 8 × 107 | CR (> 32 mo) |
| 4* | 64/F | NK/T-cell NHL (nasal) | 3 | R-CHOP (1 mo) | 3.2 × 108 | CR (relapsed 9 mo, died 18 mo) |
| 5 | 17/M | Nodular sclerosing HD stage IIa | 3 | Autologous SCT-BEAM (3 mo) | 1.2 × 108 | NR (died 8 mo) |
| 6 | 15/F | Mixed cellularity HD stage IV | 0 (residual disease) | VP16/Dox/Rituximab (1 mo) | 3 × 108 | CR (> 13 mo) |
For all patients, there was no toxicity attributed to CTL infusion.
SCT indicates stem cell transplantation; BU, busulfan; CY, cyclophosphamide; PR, partial response; CR, complete response; ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; BEAM, BCNU, etoposide, cytarabine and melphalan; NR, no response; VP-16, etoposide; and Dox, doxorubicin.
*
Patients who received 4 doses of CTLs.